ISOFOL.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:21):

Stats
Dzisiejszy wolumen	872 145
Średni wolumen	538 648
Kapitalizacja rynkowa	112.09M
EPS	SEK0 ( 2024-02-19 )
Następna data zysków	( SEK0 ) 2024-05-07
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-3.02
ATR14	SEK0.00800 (1.15%)

Wolumen Korelacja

Długi: 0.03 (neutral)

Krótki: 0.37 (neutral)

Signal:(53.202) Neutral

Isofol Medical AB (publ) Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Isofol Medical AB (publ) Korelacja - Waluta/Towar

0.35
( neutral )

0.03
( neutral )

0.00
( neutral )

0.19
( neutral )

0.00
( neutral )

0.11
( neutral )

Isofol Medical AB (publ) Finanse

Annual	2023
Przychody:	SEK721 000
Zysk brutto:	SEK-41.88M (-5 808.04 %)
EPS:	SEK-0.230

FY	2023
Przychody:	SEK721 000
Zysk brutto:	SEK-41.88M (-5 808.04 %)
EPS:	SEK-0.230

FY	2022
Przychody:	SEK12.80M
Zysk brutto:	SEK-165.71M (-1 294.89 %)
EPS:	SEK-0.970

FY	2021
Przychody:	SEK22.41M
Zysk brutto:	SEK0.00 (0.00 %)
EPS:	SEK-1.909

Financial Reports:

No articles found.

Isofol Medical AB (publ)

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.